Oncologists say they're more-or-less ready to start using biosimilar versions of easier-to-mimic therapies such as erythropoiesis-stimulating agents (ESAs), which treat anemia in cancer and kidney patients. But they're a bit more skeptical of knockoff versions of monoclonal antibodies, such as Rituxan and Avastin, a survey found. Report